Patients Receiving Intravenous Golimumab Showed Significant Improvements inSigns and Symptoms of Rheumatoid Arthritis through One Year According to New Study Findings
Data from Post Hoc Analyses of the ASPIRE and PILLAR Studies in Patients with Metavir Scores of F3 and F4 Show Sustained Viral Response Compared to Placebo